No Data
No Data
Chinese Drug Regulator Accepts ApicHope Pharmaceutical's Clinical Trial Application for Influenza Vaccine
Apichope Pharmaceutical (300723.SZ): The South China quadrivalent influenza recombinant protein vaccine has obtained clinical trial registration application acceptance.
On August 8th, Gelonhui reported that Apichope Pharmaceutical (300723.SZ) announced that its holding subsidiary, Guangdong South China Vaccine Co., Ltd. (hereinafter referred to as "South China Vaccine"), which independently developed a quadrivalent recombinant protein influenza vaccine, has applied for drug clinical trials and has received the "Acceptance Notice" from the National Medical Products Administration (Acceptance No.: CXSL2400528). This quadrivalent recombinant protein influenza vaccine, which has been accepted for clinical trial applications, can stimulate the body to produce humoral and cellular immune responses against influenza virus antigens (HA) after vaccination, and can be used for prevention.
Optimism Around ApicHope Pharmaceutical (SZSE:300723) Delivering New Earnings Growth May Be Shrinking as Stock Declines 15% This Past Week
"Breaking the mold" has become a new development topic for innovative drugs. Apichope Pharmaceutical (300723.SZ) has multiple bullish factors that continue to ferment.
The domestic innovative drug industry, such as the "crowding" in tumor targeting, has a long history. Now, under the clear policy guidance, the new issues raised by innovative drug companies are no longer a matter of "having or not," but a question of "good or not." Innovative drug companies such as Apichope Pharmaceutical concentrate resources, go deep into a certain field, make differentiation, and perhaps find a way out of the "crowded" situation. Taking the newest orally administered small-molecule GLP-1R agonist approved for clinical use by Apichope Pharmaceutical as an example, according to public announcements, APH01727 tablets are a highly active and highly selective glucagon-like peptide-1 receptor agonist developed independently by Apichope Pharmaceutical.
Apichope Pharmaceutical (300723.SZ): As of July 19, the total number of shareholders of the company was 13,043.
Apichope Pharmaceutical (300723.SZ) stated on the investor interaction platform on July 31 that as of July 19, 2024, the total number of company shareholders was 13,043.
HK stocks fluctuate | SSY Group (02005) fell more than 15% due to concerns over the breach of centralized procurement, Apichope Pharmaceutical was fined and returned 266 million yuan for suspected bid rigging.
SSY Group (02005) fell more than 15% in the afternoon, and as of press time, it fell by 14.88% to HKD 3.66, with a turnover of HKD 62.4743 million.
No Data